Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism
- PMID: 23903802
- DOI: 10.1007/s10157-013-0844-2
Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism
Abstract
Background: Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease. Our primary objective was to evaluate the efficacy of oral paricalcitol versus oral calcitriol on serum intact parathyroid hormone (iPTH) and mineral bone parameters in continuous ambulatory peritoneal dialysis (CAPD) patients with SHPT. The secondary objective was to analyze highly sensitive C-reactive protein (hsCRP) and peritoneal membrane function in both groups.
Methods: This was a prospective randomized control trial. CAPD patients with SHPT were randomized to paricalcitol or calcitriol for 15 weeks. Serum intact iPTH, calcium, phosphate and alkaline phosphatase (ALP) were measured at baseline and every 3 weeks. Serum hsCRP and peritoneal membrane functions were measured at baseline and at week 15.
Results: A total of 26 patients were enrolled and randomized-12 to paricalcitol and 14 to calcitriol. Serum iPTH reduced significantly in both groups and there was no difference in the incidence of ≥50 % reduction of iPTH between both groups. There was a significant increase in serum calcium in both groups but there were no differences in serum phosphorus across the visits. The incidence of hypercalcemia was the same in both groups. Serum calcium-phosphorus (Ca × P) product increased in the paricalcitol group but decreased in the calcitriol group. Serum ALP decreased significantly in both groups. There were also no differences in pre- and post-treatment serum hsCRP and peritoneal function test (PFT) in both groups.
Conclusion: Both oral paricalcitol and calcitriol were equally efficacious in reducing serum iPTH but were associated with significantly higher serum calcium. Serum Ca × P product increased in the paricalcitol group and decreased in the calcitriol group. Serum hsCRP level and PFT were not affected by either treatment. A larger randomized controlled trial is indicated to confirm these initial findings.
Similar articles
-
Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.Nephrology (Carlton). 2013 Mar;18(3):194-200. doi: 10.1111/nep.12029. Nephrology (Carlton). 2013. PMID: 23311404 Clinical Trial.
-
Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.Ren Fail. 2012;34(3):297-303. doi: 10.3109/0886022X.2011.647298. Epub 2012 Jan 17. Ren Fail. 2012. PMID: 22251408 Clinical Trial.
-
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.Am J Nephrol. 2008;28(1):97-106. doi: 10.1159/000109398. Epub 2007 Oct 3. Am J Nephrol. 2008. PMID: 17914251 Clinical Trial.
-
Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Expert Opin Pharmacother. 2008. PMID: 18377338 Review.
-
A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD).Eur Rev Med Pharmacol Sci. 2022 Jan;26(1):232-239. doi: 10.26355/eurrev_202201_27773. Eur Rev Med Pharmacol Sci. 2022. PMID: 35049000
Cited by
-
Vitamin D: are all compounds equal?Clin Kidney J. 2025 Mar 13;18(Suppl 1):i61-i96. doi: 10.1093/ckj/sfae417. eCollection 2025 Mar. Clin Kidney J. 2025. PMID: 40083955 Free PMC article.
-
Vitamin D and Clinical Outcomes in Dialysis.Semin Dial. 2015 Nov-Dec;28(6):604-9. doi: 10.1111/sdi.12446. Epub 2015 Oct 1. Semin Dial. 2015. PMID: 26424141 Free PMC article. Review.
-
Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.BMC Nephrol. 2017 Aug 25;18(1):272. doi: 10.1186/s12882-017-0691-6. BMC Nephrol. 2017. PMID: 28841848 Free PMC article.
-
Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review.J Nephrol. 2014 Oct;27(5):483-94. doi: 10.1007/s40620-014-0120-x. Epub 2014 Jul 11. J Nephrol. 2014. PMID: 25012237
-
Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Int Urol Nephrol. 2016 Apr;48(4):571-84. doi: 10.1007/s11255-015-1195-6. Epub 2016 Jan 9. Int Urol Nephrol. 2016. PMID: 26748501
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials